U.S. markets closed
  • S&P Futures

    3,832.25
    +4.25 (+0.11%)
     
  • Dow Futures

    31,394.00
    +23.00 (+0.07%)
     
  • Nasdaq Futures

    12,799.75
    -32.00 (-0.25%)
     
  • Russell 2000 Futures

    2,192.50
    -7.50 (-0.34%)
     
  • Crude Oil

    63.07
    -0.46 (-0.72%)
     
  • Gold

    1,766.90
    -8.50 (-0.48%)
     
  • Silver

    27.26
    -0.42 (-1.54%)
     
  • EUR/USD

    1.2158
    -0.0028 (-0.23%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.3987
    -0.0026 (-0.19%)
     
  • USD/JPY

    106.2330
    +0.0030 (+0.00%)
     
  • BTC-USD

    46,993.19
    -2,749.46 (-5.53%)
     
  • CMC Crypto 200

    936.95
    -57.71 (-5.80%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,458.45
    -709.82 (-2.35%)
     

Recap: Exact Sciences Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Exact Sciences (NASDAQ:EXAS) fell in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 59.46% over the past year to ($0.15), which beat the estimate of ($0.22).

Revenue of $466,339,000 higher by 57.77% year over year, which beat the estimate of $446,220,000.

Looking Ahead

Exact Sciences Q4 Adj EPS $(0.15) Beats $(0.22) Est., Sales $466.30M Beat $446.22M Estimate

Details Of The Call

Date: Feb 16, 2021

Time: 05:00 PM

View more earnings on EXAS

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.exactsciences.com%2F&eventid=2947790&sessionid=1&key=7A6EAD362F45519771EB10F00535B95F&regTag=&V2=false&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $159.54

52-week low: $35.25

Price action over last quarter: Up 14.49%

Company Overview

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.